223 related articles for article (PubMed ID: 34918174)
21. Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization.
Lee BC; Jeong YY; Heo SH; Kim HO; Park C; Shin SS; Cho SB; Koh YS
Acad Radiol; 2022 Sep; 29(9):e178-e188. PubMed ID: 35151549
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
[TBL] [Abstract][Full Text] [Related]
23. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma.
Carling U; Røsok B; Line PD; Dorenberg EJ
Acta Radiol; 2019 Jun; 60(6):702-709. PubMed ID: 30205701
[TBL] [Abstract][Full Text] [Related]
24. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
25. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
[TBL] [Abstract][Full Text] [Related]
26. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
27. Prediction Model for Intermediate-Stage Hepatocellular Carcinoma Response to Transarterial Chemoembolization.
Jia F; Wu B; Yan R; Li L; Wang K; Han D
J Magn Reson Imaging; 2020 Dec; 52(6):1657-1667. PubMed ID: 32424881
[TBL] [Abstract][Full Text] [Related]
28. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
[TBL] [Abstract][Full Text] [Related]
29. Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features.
Li ZW; Ren AH; Yang DW; Xu H; Wei J; Yuan CW; Wang ZC; Yang ZH
BMC Med Imaging; 2022 Oct; 22(1):176. PubMed ID: 36207686
[TBL] [Abstract][Full Text] [Related]
30. Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study.
Wang DD; Zhang JF; Zhang LH; Niu M; Jiang HJ; Jia FC; Feng ST
Hepatobiliary Pancreat Dis Int; 2023 Dec; 22(6):594-604. PubMed ID: 36456428
[TBL] [Abstract][Full Text] [Related]
31. Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma.
Bai H; Meng S; Xiong C; Liu Z; Shi W; Ren Q; Xia W; Zhao X; Jian J; Song Y; Ni C; Gao X; Li Z
Cardiovasc Intervent Radiol; 2022 Oct; 45(10):1524-1533. PubMed ID: 35896687
[TBL] [Abstract][Full Text] [Related]
32. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
33. Selection Between Liver Resection Versus Transarterial Chemoembolization in Hepatocellular Carcinoma: A Multicenter Study.
Fu S; Wei J; Zhang J; Dong D; Song J; Li Y; Duan C; Zhang S; Li X; Gu D; Chen X; Hao X; He X; Yan J; Liu Z; Tian J; Lu L
Clin Transl Gastroenterol; 2019 Aug; 10(8):e00070. PubMed ID: 31373932
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.
Adhoute X; Pénaranda G; Raoul JL; Pietri O; Bronowicki JP; Castellani P; Perrier H; Monnet O; Bayle O; Oules V; Pol B; Beaurain P; Muller C; Cassagneau P; Bourlière M
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1414-1423. PubMed ID: 31045613
[TBL] [Abstract][Full Text] [Related]
35. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound.
Liu D; Liu F; Xie X; Su L; Liu M; Xie X; Kuang M; Huang G; Wang Y; Zhou H; Wang K; Lin M; Tian J
Eur Radiol; 2020 Apr; 30(4):2365-2376. PubMed ID: 31900703
[TBL] [Abstract][Full Text] [Related]
36. Transarterial Chemoembolization (TACE) Using Mitomycin with or without Irinotecan for Hepatocellular Carcinoma in European Patients.
Gruber-Rouh T; Kamal A; Eichler K; Naguib NN; Beeres M; Langenbach M; Vogl TJ
Oncol Res Treat; 2018; 41(7-8):438-442. PubMed ID: 30007958
[TBL] [Abstract][Full Text] [Related]
37. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
[TBL] [Abstract][Full Text] [Related]
38. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.
Pinato DJ; Sharma R; Allara E; Yen C; Arizumi T; Kubota K; Bettinger D; Jang JW; Smirne C; Kim YW; Kudo M; Howell J; Ramaswami R; Burlone ME; Guerra V; Thimme R; Ishizuka M; Stebbing J; Pirisi M; Carr BI
J Hepatol; 2017 Feb; 66(2):338-346. PubMed ID: 27677714
[TBL] [Abstract][Full Text] [Related]
39. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
40. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy.
Gross A; Albrecht T
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):402-410. PubMed ID: 31705244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
